Get the Stockscreener App
97.74
1.02%
-1.01
Spyre Therapeutics Inc stock is traded at $97.74, with a volume of 778.88K.
It is down -1.02% in the last 24 hours and up +30.18% over the past month.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$98.75
Open:
$98.75
24h Volume:
778.88K
Relative Volume:
0.55
Market Cap:
$8.49B
Revenue:
$688.00K
Net Income/Loss:
$-168.74M
P/E Ratio:
-41.46
EPS:
-2.3577
Net Cash Flow:
$-185.87M
1W Performance:
+12.82%
1M Performance:
+30.18%
6M Performance:
+219.31%
1Y Performance:
+512.41%
1-Day Range:
$94.13
$99.34
1-Week Range:
$86.60
$99.34
52-Week Range:
$14.51
$102.06
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
97.74 | 8.49B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY - TradingView
Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st
Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading - StocksToTrade
Spyre falls after $2M insider sale - MSN
Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics (SYRE) Study result Summary - Quartr
Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary - Quartr
Spyre Therapeutics stock hits 52-week high at 51.08 USD - Investing.com
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative - Sahm
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares By Investing.com - Investing.com India
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $730k in stock - Investing.com
Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares - Investing.com
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares - Investing.com Nigeria
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre gives six new hires equity awards worth 58,843 options - Stock Titan
Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com - Investing.com Canada
Form 144 | Spyre Therapeutics(SYRE.US) Director Proposes to Sell 4 Million in Common Stocks - Moomoo
SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice - Stock Titan
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE) - Seeking Alpha
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - TradingView
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design - Yahoo Finance
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts - Yahoo Finance
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing - Moomoo
Spyre Therapeutics, Inc.(NasdaqGS:SYRE) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Spyre Therapeutics, Inc.(NasdaqGS: SYRE) dropped from Russell 2500 Value Benchmark - marketscreener.com
Spyre Therapeutics Files for Offering up to a - Moomoo
Form S-3ASR Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com India
Form 4 Spyre Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock - Investing.com UK
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics CFO Burrows sells $1.3m in SYRE stock By Investing.com - Investing.com South Africa
Spyre Therapeutics Chief Financial Officer Sold Shares Worth Over $1.3M - TradingView
Spyre Therapeutics (SYRE) CFO sells 15,000 shares after option exercise - Stock Titan
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Burrows Scott L - Moomoo
Enterprise value to EBIT forward of Spyre Therapeutics, Inc. – BOATS:SYRE - TradingView
Spyre Therapeutics Files For Mixed Shelf Size Not DisclosedFiling - TradingView
Spyre Therapeutics files prospectus for mixed shelf - scanx.trade
Spyre Therapeutics (NASDAQ: SYRE) launches $500M at‑the‑market program - Stock Titan
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset - Seeking Alpha
Enterprise value to EBITDA forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics, Inc Actuals & Estimates (NASDAQ:SYRE) - TradingView
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):